Premium
Review article: non‐alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery
Author(s) -
DE RIDDER R. J. J.,
SCHOON E. J.,
SMULDERS J. F.,
VAN HOUT G. C. M.,
STOCKBRÜGGER R. W.,
KOEK G. H.
Publication year - 2007
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2007.03483.x
Subject(s) - medicine , fatty liver , steatosis , obesity , disease , weight loss , fibrosis , gastroenterology , morbidly obese , surgery , liver disease , alcoholic liver disease , cirrhosis
Summary Background Morbid obesity is strongly associated with non‐alcoholic fatty liver disease. The effects of bariatric surgery on liver tests an histolological abnormalities after weight loss are controversial. Aim To review the literature on the prevalence of non‐alcoholic fatty liver disease in patients with morbid obesity with respect to laboratory and histopathological parameters and the effect of weight loss on these parameters after bariatric surgery. Results Standard liver tests do not seem to be a sensitive tool for the assessment and follow‐up of non‐alcoholic fatty liver disease in obesity. In nearly all patients with morbid obesity, histological abnormalities reflecting non‐alcoholic fatty liver disease are present. Bariatric surgery in these patients will decrease the grade of steatosis. However, there are some concerns about the effect of bariatric surgery on hepatic inflammation and fibrosis. In particular, older follow‐up studies reported negative results as opposed to more recent studies, which also showed improvement in hepatic inflammation and fibrosis. Unfortunately, most studies had limitations because of the selection of patients. Conclusion Despite limitations in many studies, bariatric surgery seems to be a promising treatment in patients with obesity presenting with non‐alcoholic fatty liver disease.